These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 35113170)

  • 1. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
    Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
    Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.
    Potere N; Del Buono MG; Caricchio R; Cremer PC; Vecchié A; Porreca E; Dalla Gasperina D; Dentali F; Abbate A; Bonaventura A
    EBioMedicine; 2022 Nov; 85():104299. PubMed ID: 36209522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of inflammasome NLRP3 in the pathophysiology of viral infections: A focus on SARS-CoV-2 infection].
    Chemarin M; Dufies O; Mazet A; Mellan E; Coudereau R; Py BF; Boyer L; Venet F
    Med Sci (Paris); 2022; 38(6-7):545-552. PubMed ID: 35766852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in the relationship between NLRP3 inflammasome and lung injury in COVID-19].
    Ren Z; Che P; Li Z; Mo M; Zhang S; Zhang Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Sep; 37(9):844-850. PubMed ID: 34533131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease.
    Vecchié A; Del Buono MG; Chiabrando GJ; Dentali F; Abbate A; Bonaventura A
    Curr Cardiol Rep; 2021 Oct; 23(11):157. PubMed ID: 34599390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bystander monocytic cells drive infection-independent NLRP3 inflammasome response to SARS-CoV-2.
    Hsieh LL; Looney M; Figueroa A; Massaccesi G; Stavrakis G; Anaya EU; D'Alessio FR; Ordonez AA; Pekosz AS; DeFilippis VR; Karakousis PC; Karaba AH; Cox AL
    mBio; 2024 Oct; 15(10):e0081024. PubMed ID: 39240187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.
    Saeedi-Boroujeni A; Mahmoudian-Sani MR; Nashibi R; Houshmandfar S; Tahmaseby Gandomkari S; Khodadadi A
    Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):247-258. PubMed ID: 34015982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment.
    Bertoni A; Penco F; Mollica H; Bocca P; Prigione I; Corcione A; Cangelosi D; Schena F; Del Zotto G; Amaro A; Paladino N; Pontali E; Feasi M; Signa S; Bustaffa M; Caorsi R; Palmeri S; Contini P; De Palma R; Pfeffer U; Uva P; Rubartelli A; Gattorno M; Volpi S
    J Allergy Clin Immunol; 2022 Oct; 150(4):796-805. PubMed ID: 35835255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
    Zhao N; Di B; Xu LL
    Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.
    Amaral NB; Rodrigues TS; Giannini MC; Lopes MI; Bonjorno LP; Menezes PISO; Dib SM; Gigante SLG; Benatti MN; Rezek UC; Emrich-Filho LL; Sousa BA; Almeida SCL; Luppino-Assad R; Veras FP; Schneider AH; Leiria LOS; Cunha LD; Alves-Filho JC; Cunha TM; Arruda E; Miranda CH; Pazin-Filho A; Auxiliadora-Martins M; Borges MC; Fonseca BAL; Bollela VR; Del-Ben CM; Cunha FQ; Santana RC; Vilar FC; Zamboni DS; Louzada-Junior P; Oliveira RDR
    Inflamm Res; 2023 May; 72(5):895-899. PubMed ID: 36917217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis.
    Potere N; Garrad E; Kanthi Y; Di Nisio M; Kaplanski G; Bonaventura A; Connors JM; De Caterina R; Abbate A
    Cardiovasc Res; 2023 Sep; 119(11):2046-2060. PubMed ID: 37253117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the NLRP3 inflammasome in cardiovascular diseases.
    Toldo S; Mezzaroma E; Buckley LF; Potere N; Di Nisio M; Biondi-Zoccai G; Van Tassell BW; Abbate A
    Pharmacol Ther; 2022 Aug; 236():108053. PubMed ID: 34906598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.
    Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG
    Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.
    Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR
    Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
    Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
    Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1β production.
    Gong Z; Zhao S; Zhou J; Yan J; Wang L; Du X; Li H; Chen Y; Cai W; Wu J
    Mol Immunol; 2018 Dec; 104():11-19. PubMed ID: 30396035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome.
    Otani K; Watanabe T; Shimada S; Takeda S; Itani S; Higashimori A; Nadatani Y; Nagami Y; Tanaka F; Kamata N; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Fujiwara Y; Arakawa T
    Sci Rep; 2016 Sep; 6():32587. PubMed ID: 27585971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice.
    Zeng J; Xie X; Feng XL; Xu L; Han JB; Yu D; Zou QC; Liu Q; Li X; Ma G; Li MH; Yao YG
    EBioMedicine; 2022 Jan; 75():103803. PubMed ID: 34979342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial.
    Rahhal A; Najim M; Aljundi AH; Mahfouz A; Alyafei SM; Awaisu A; Habib MB; Obeidat I; Faisal MM; Alanzi MA; Nair AP; Elhassan A; Al-Dushain A; Abdelmajid AA; Abdelgader AE; Moursi AMA; Alharafsheh AEN; Kamar MRA; Goravey W; Omar AS; Abukhattab M; Khatib MY; Mohamedali MG; AlMaslamani MAR; Alemadi S
    Medicine (Baltimore); 2022 Sep; 101(39):e30618. PubMed ID: 36181009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.